Terns Pharmaceuticals

Substrate placeholder — needs review

Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals Following Drug Data

Merck announced last month its acquisition of Terns Pharmaceuticals for $6.7 billion. The deal follows promising early data from Terns' experimental leukemia drug. New details have emerged on the pricing negotiations.